Potent inhibitory effect of selective D2 and D3 agonists on dopamine-responsive dorsomedial arcuate neurons in brain slices of estrogen-primed rats.
The possible involvement of dopamine D2 and D3 receptors in the action of dopamine (DA) on inhibiting dorsomedial arcuate nucleus (dmARN) neurons in brain slices was determined in this study. Fresh brain slices were prepared from ovariectomized, estrogen-primed Sprague-Dawley rats and used for extracellular single-unit recording. The dmARN neurons were first identified by their inhibitory responses to DA and then tested with PHNO and/or PD128907, selective D2 and D3 agonists, respectively. PD128907 in 5-50 nmole doses significantly inhibited the majority of DA-responsive dmARN neurons (86.3% of 44 units). Moreover, PHNO in 5-25 nmole doses inhibited all DA-responsive neurons tested (100% of 34 units). The inhibitory effects of PHNO and PD128907 were not only prominent; but also persisted in low Ca2+, high Mg2+ medium, indicating that they were acting directly on the recorded neuron. Pretreatment of either raclopride or U99194A, D2 and D3 receptor antagonists respectively, reversed the effects of DA in a few trials. In contrast, SKF81297, a D1 receptor agonist, induced variable responses in dmARN neurons. These results clearly indicate that DA may act through D2 and/or D3 receptors to exhibit an inhibitory effect on presumed TIDA neurons in dmARN.
Liang
S L
SL
Department of Physiology, School of Life Science, National Yang-Ming University, Taipei, Taiwan, ROC.
Pan
J T
JT
D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000166:cytology / Q000187:drug effects; D001552:Benzazepines / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D001921:Brain / Q000166:cytology / Q000187:drug effects; D004298:Dopamine / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D004347:Drug Interactions; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D020645:Mediodorsal Thalamic Nucleus / Q000166:cytology / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010078:Oxazines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3
D001552:Benzazepines; D001578:Benzopyrans; D018491:Dopamine Agonists; C493595:Drd3 protein, rat; D004967:Estrogens; D010078:Oxazines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C062458:3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol; C042631:naxagolide; C067113:SK&F 81297; D004298:Dopamine